*Department of Medical Oncology, Xianyang Central Hospital, Shanxi

†Department of Surgical Oncology, General Hospital of Ningxia Medical University

‡Department of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan

§Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining, China

L.N. and Y.L. contributed equally.

This study protocol was reviewed and approved by the Ethics Committee of Ningxia Medical University General Hospital (No. 2023-12), and the final approval date was May 4, 2023. Patient consent was waived due to the fact that this is a retrospective study, and the study conforms to the provisions of the Declaration of Helsinki.

L.N., X.L., and J.Z.: conceived the study and designed the protocol. X.H., R.H., and Y.X. performed the literature search and selected. L.N., Y.L., and X.H.: extracted the relevant information and synthesized the data. L.N. and Y.L. wrote the first draft of the paper.

The authors declare no conflicts of interest.

Correspondence: Xinlan Liu, MD, Department of oncology, General Hospital of Ningxia Medical University, No. 804 Shengli Road, Xingqing District, Yinchuan, 750004, China ([email protected]); Jiuda Zhao, MD, Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining 810000, China ([email protected]).

Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal's website, www.amjclinicaloncology.com.